Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,161.20 | 13.20 | -0.14% |
| CAC 40 | 8,323.28 | 49.44 | 0.60% |
| DAX 40 | 25,014.87 | 293.41 | 1.19% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,386.23 | 16.48 | 0.16% |
| HKSE | 27,375.77 | 348.61 | 1.29% |
| NASDAQ | 23,238.67 | 207.46 | 0.90% |
| Nikkei 225 | 57,708.10 | 1,344.16 | 2.38% |
| NZX 50 Index | 13,486.04 | 39.67 | 0.30% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 8,894.00 | 17.60 | -0.20% |
| SSE Composite Index | 4,130.80 | 7.71 | 0.19% |